M aintenance of genomic stability is fundamental for the faithful propagation of genomic information and, hence, for the vitality of every cell type. Genome integrity is constantly jeopardized by a diverse array of insults emanating from the organism's interaction with the environment (e.g., ionizing radiation, chemicals), endogenous sources intrinsic to cellular physiology (e.g., free radicals, collapsed replication forks), or specialized developmental programs (e.g., somatic recombination in lymphocytes) (1) . In this regard, B lymphocytes are particularly challenged. Not only are vast numbers of B cells continuously being produced during adult life but they also undergo three distinct modes of genetic alterations associated with DNA strand breaks: VDJ recombination, Ab class switch recombination (CSR), 3 and somatic hypermutation. If such damage is dealt with inappropriately, tumorigenesis or immune deficiency may ensue (2, 3) . A drastic example for an inherited genetic defect revealing this relationship is given by Bloom's syndrome (BS), a rare autosomal recessive disorder in which the RecQ helicase BLM is mutated (4) . Although its multiple functions remain incompletely characterized, BLM is thought to act as "roadblock remover" during replication, chiefly through unwinding of secondary DNA structures detrimental to replication fork progression. It is also assumed to function as "anti-recombinase", either through disruption of early intermediates of homologous recombination at sites of limited homology (discussed in Ref. 5) or through resolution of Holiday junctions yielding noncrossover products (6) . Indeed, grossly elevated frequencies of sister chromatid exchanges are a typical feature for BS cells (7) . The hallmark characteristics of BS patients are small stature, male infertility, a profound susceptibility to most cancer types, and immunodeficiency (7) , with the latter two features accounting for early death (8) . Among body tissues, the effect of BLM deficiency on the immune system appears particularly severe as non-Hodgkin's lymphomas and leukemias dominate the cancer spectrum (8) , whereas impaired hypersensitivity and hypoglobulinemia imply a generally compromised adaptive immunity. Indeed, BS patients frequently develop serious ear and respiratory tract infections (7) . Data from multiple studies point toward defects in the B cell lineage, exemplified by low concentrations of serum IgM (9, 10) or non-IgM isotypes (11, 12) , compromised mitogen-induced B cell responses (10) , or impaired generation of non-IgM-secreting Ab-forming cells (AFCs) in vitro (11) . These findings are compatible with impaired B cell development or differentiation, including defective CSR.
During B cell development in the mouse bone marrow, B220 gene segments at the Ig H chain locus to generate a productive V H D H J H exon. This VDJ joint is subsequently expressed as class H chain in combination with a surrogate L chain forming the pre-BCR (Hardy fractions (Fr.) A-C) (13) . Pre-BCR expression of precursor B cells triggers a proliferative burst (Fr. CЈ) followed by a resting phase (Fr. D), at which the cells rearrange Ig or Ig L chain genes to become IgM ϩ immature (Fr. E) B cells. Fr. E cells migrate to the spleen where they complete their maturation to join the pool of long-lived follicular (FO) or marginal zone (MZ) B cells, collectively referred to as B2 cells (14 -16) . FO cells, chiefly localized in the follicles of spleen and lymph nodes, participate in T cell-dependent (TD) Ab responses and occasionally recirculate through the bone marrow where they appear as IgM ϩ IgD ϩ Fr. F cells (17) . MZ B cells, located in the marginal zone of the spleen, are able to rapidly respond to blood-borne pathogens through predominantly T cell-independent (TI) Ab responses (15) . B1 cells, mainly populating peritoneal and pleural body serosa, are thought to produce the bulk of "natural Abs" that are enriched in specificities to common pathogens. They thus function as a "first line of defense" through rapid TI Ab responses. In contrast to B2 cells, B1 cells seem to be generated predominantly during fetal life and early ontogeny, after which they propagate themselves throughout adulthood. Furthermore, CD5 expression distinguishes CD5 ϩ B1a and CD5
Ϫ B1b cells in the peritoneal cavity (14, 18) . All four principal B cell subsets are capable of undergoing CSR to generate Abs of the IgG, IgE, and IgA subclasses. During CSR, the V H D H J H exon, which by default forms a transcription unit with the C/C␦ constant region genes, is joined to a downstream C H region. This process involves the generation of double strand breaks (DSBs), deletion of the intervening DNA, and DSB repair by general DNA response factors (19) . CSR critically depends on the enzyme activation-induced cytidine deaminase (AID) (20) and prior transcription through the intronic switch (S) regions of the participating C H genes (21) . Such transcription at a particular C H locus is widely thought to generate R-loop structures within the S region, thereby exposing cytidines in the nontemplate strand as targets for AID-mediated deamination (19) . Interestingly, due to the abundance of guanines in the nontemplate strand, S regions likely adopt stable DNA secondary structures upon transcription such as G4 quartets (19, 22) that represent classical substrates for the unwinding activity of BLM (5, 23, 24) . Also, BLM is known to directly interact with factors proven to participate in CSR such as the mismatch repair protein Mlh1 (25, 26) . A direct or indirect role for BLM in the mechanism of CSR is therefore conceivable.
To investigate the role of BLM in B cell biology and circumvent the embryonic lethality in conventional Blm knockout mice (27) , we selectively ablated murine Blm in B-lineage cells. In accordance with and complementary to our earlier report where we encountered an impaired T cell lineage in T cell-specific knockout mice (28) , we describe herein a dramatic effect of Blm deficiency on B lymphocytes. In conditional knockout mice, we found compromised B cell development and maintenance, strongly impaired TD and TI Ab responses after immunization, and a propensity for developing B cell lymphomas. Our results from in vitro experiments are compatible with a minor yet nonessential role for Blm in CSR.
Materials and Methods

Mice
The mutant Blm alleles had been generated previously in our laboratory: the Blm ⌬ allele (Blm tm1Ches ) is rendered nonfunctional by disruption of exon 8 upstream of the helicase domain resulting from an insertion of a Neo resistance cassette (27) . The Blm f allele (Blm tm4Ches ) contains a loxPflanked (floxed) exon 8 (29) that is excised upon Cre expression (Blm tm3Ches ), causing a premature termination of Blm translation (30) . Mb1-Cre mice expressing a humanized Cre recombinase under the control of the Ig␣ promoter/enhancer elements were described recently (31) , and the Trp53 Ϫ/Ϫ line (32) has been carried in this laboratory for years. All mice were housed in specific pathogen-free environments. Experimental procedures were approved by the institutional review board of the animal facility at the Harvard Medical School.
Tumor cohorts, histological, and immunohistochemical analysis of tumor material
Mice set up to allow for tumor development were immunized twice at the age of 9 -12 and 14 -17 wk i.p. with 10 8 SRBCs (Cedarlane Laboratories) in PBS, monitored twice per week, and sacrificed when overtly sick. Spleens and macroscopically cancerous organs were archived in Optimal Fix (American MasterTech Scientific), and pathological examination was conducted on H&E-stained organ sections by Dr. Roderick Bronson at the Harvard Medical School Rodent Histopathology Core.
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. After rehydration, slides were pretreated with 10 mM citrate (pH 6.0) (for anti-B220 and PNA), 1 mM EDTA (pH 8.0) (for anti-CD3), and Dako pH 9 buffer (for anti-TdT) in a steam pressure cooker. After treatment with peroxidase block (Dako), slides were incubated with either rat anti-murine B220 (RA3-6B2; BD Biosciences) followed by polyclonal rabbit anti-rat Ig Ab (Dako), or polyclonal rabbit anti-CD3 (Cell Marque, catalog no. CMC363), or polyclonal rabbit anti-TdT (Dako, catalog no. A3524), and detected with the anti-rabbit EnVisionϩ kit (Dako) as per the manufacturer's instructions. To reveal cytoplasmic Ig, no primary Ab was used. Instead, slides were only stained with the antimouse EnVisionϩ kit (Dako). To detect peanut agglutinin (PNA) binding, slides were treated with biotinylated PNA (Vector Laboratories) followed by strepavidin-HRP. All immunoperoxidase stains were developed using a DAB chromogen (Dako) and counterstained with hematoxylin.
Analysis of germinal center (GC) development
Fifteen-to 17-wk-old mice were immunized i.p. with 10 8 SRBCs in PBS and sacrificed after 8, 12, and 18 days. Spleens were snap-frozen, and tissue sections were cut on a cryostat microtome followed by formalin fixation. Ag was retrieved by incubating slides in 1 mM EDTA (pH 7.5) for 30 min at 95°C. After treatment with an avidin/biotin blocking kit (Vector Laboratories), GC B cells were identified by incubation with biotinylated PNA (Vector Laboratories) followed by avidin-coupled HRP (Dako). Peroxidase activity was visualized employing the AEC peroxidase substrate kit (Vector Laboratories). GC and total section area measurements were performed on micrographs using Openlab software (Improvision).
Cell preparation and flow cytometry
Tibiae and peritoneal cavities were flushed with HBSS ϩ 3% BSA to collect bone marrow and peritoneal exudate cells, respectively. Single-cell suspensions from spleens and thymi were prepared using the same buffer. Bone marrow and spleen preparations were subjected to erythrocyte lysis in 0.165 M NH 4 Cl (pH 7.5) solution, and surface labeling was done using the following fluorescently conjugated Abs: anti-B220 (RA3-6B2), anti-
, anti-TER119 (TER119), AA4.1 (eBioscience, BD Biosciences, or Caltag Laboratories), and polyclonal goat anti-IgM, antiIgG2a, and anti-IgG3 (SouthernBiotech). To exclude dead cells, 1 g/ml propidium iodide was added immediately before analysis. Flow cytometric analysis and cell sorting was performed on a FACSCalibur cytometer and FACSAria cell sorter (BD Biosciences), respectively, and data were analyzed using FlowJo software (Tree Star).
Blm deletion PCR
Blm deletion on genomic DNA from FACS-purified lymphocyte populations was determined semiquantitatively using a three-primer PCR assay in which a 330-bp product and a 120-bp product are amplified from the floxed Blm tm4Ches and the deleted Blm tm3Ches allele, respectively. PCR and assessment of the approximate deletion efficiencies was done exactly as described (28) .
Induction of TI and TD immune responses, ELISA, and ELISPOT
Eleven-to 19-wk-old mice were immunized i.p. with 10 g NP 41 -Ficoll (4-hydroxy-3-nitrophenylacetyl-AECM-Ficoll) in PBS or 10 g NP 25 -CGG (4-hydroxy-3-nitrophenylacetyl chicken-␥-globulin) precipitated in alum, and bled from tail veins at regular intervals.
Serum Ig concentrations from 7-to 10-wk-old naive mice were measured by ELISA using the "SBA clonotyping system" and the "mouse Ig isotype panel" as reference standards (both from SouthernBiotech). Relative NP-specific Ig levels were determined similarly with the following exceptions: ELISA plates were coated with 10 g/ml NP 30 -BSA in PBS and pools of reference sera from 10 mice (all genotypes) that had been immunized using the same protocols served as standards.
Quantification of IgM-, IgG1-, and IgG2a-secreting AFCs was done by culturing bone marrow cells from NP-CGG-immunized mice on NP-BSAcoated polyvinylidene difluoride membranes (Pall) for 18 h at 37°C. Bound NP-specific Igs were detected using the appropriate HRP-conjugated Abs from the SBA clonotyping system and visualized by chemiluminescence. All NP conjugates were purchased from Biosearch Technologies.
BrdU labeling
Cohorts of (Trp53 ϩ/ϩ or Trp53 ϩ/Ϫ ) conditional knockout and control mice were given 0.8 mg/ml BrdU (Sigma-Aldrich) in the drinking water for 2 wk. Groups of 4 ϩ 4 mice were sacrificed after 0, 8, 15, 22, and 33 days following the pulse period. Bone marrow, spleen, and peritoneal exudate cells were surface-labeled, and BrdU incorporation was determined utilizing a BrdU flow kit (BD Biosciences).
In vitro CSR assays
Resting splenic CD43
Ϫ B cells were isolated by CD43 microbead-mediated negative selection (Miltenyi Biotec), labeled with 5 M CFSE (Molecular Probes) for 10 min at 37°C, and cultured at 5 ϫ 10 5 cells/ml in complete RPMI 1640 ϩ 10% FCS for 4 days with 20 g/ml LPS (SigmaAldrich), LPS ϩ 50 ng/ml recombinant IFN-␥ (BioSource International), or LPS ϩ 20 ng/ml recombinant IL-4 (eBioscience). To prepare RNA for real-time RT-PCR, a portion of the cells was harvested after 2 days, lysed in TRIzol reagent (Invitrogen), and stored as lysate at Ϫ80°C until used for RT. On day 4, cells were harvested, stained for surface expression of IgM, IgG1, IgG3, or IgG2a, and analyzed by cytometry in the presence of 1 g/ml 7-aminoactinomycin D to discriminate dead cells.
Cell cycle and cytogenetic analysis
Splenic B cells were prepared and cultured as explained above with the modification that a combination of 1 g/ml anti-CD40 Ab (HM40-3; eBioscience) and 25 ng/ml IL-4 was used as stimulus. On day 3, 25 ng/ml KaryoMax Colcemid (Invitrogen) was added for the last 90 min of culture. Subsequently, 2 ϫ 10 6 cells were harvested and surface-labeled with antiIgG1 Ab, followed by fixation and permeabilization using BD Cytofix/ Cytoperm and BD Perm/Wash buffers (BD Biosciences). Cells were incubated with 0.5 mg/ml RNase A (Roche) in PBS for 30 min at 37°C, after which 20 g/ml propidium iodide was added for another 30-min incubation on ice, followed by DNA content analysis at the cytometer.
For DNA damage analysis, Colcemid-treated cells were swelled in 0.075 M KCl solution for 12 min at 37°C and fixed with methanol/acetic acid (3:1). Metaphase spreads were prepared and stained with Giemsa reagents following standard procedures.
Quantitative RT-PCR
Total RNA stored in TRIzol (see above) was extracted according to the manufacturer's recommendations and reverse-transcribed with SuperScript III reverse transcriptase and oligo(dT) 20 primers, followed by RNase H treatment. Real-time PCR was done on an AB 7300 machine (Applied Biosystems) using the QuantiTect SYBR Green PCR system (Qiagen) according to the Qiagen protocol. Specificity of the primer pairs was ensured by analysis of dissociation curves and verification of expected fragment sizes by gel electrophoresis. Serially diluted cDNA samples were employed to ensure comparable amplification efficiencies of target and endogenous reference genes (␤-actin). Relative mRNA abundance was calculated using the comparative C T method. Primers were: ␤-actin: 5Ј-CTTTTCCAGCCTTCCTTCTTGG-3Ј and 5Ј-CAGCACTGTGTTG GCATAGAGG-3Ј; germline (GL): 5Ј-CTCGGTGGCTTTGAAGGA AC-3Ј and 5Ј-TGGTGCTGGGCAGGAAGT-3Ј; ␥1 GL: 5Ј-TCGAGA AGCCTGAGGAATGTG-3Ј and 5Ј-ATGGAGTTAGTTTGGGCAGC A-3Ј; ␥2a GL: 5Ј-CTGGCAGTACCGATGCAGG-3Ј and 5Ј-GC CAGTTGTATCTCCACACACAG-3Ј; ␥3 GL: 5Ј-GCAAGATCT CTGCAGCAGAAATC-3Ј and 5Ј-CCAGGGACCAAGGGATAGACA-3Ј; ␥1 postswitch (PS): 5Ј-TCTGGACCTCTCCGAAACCA-3Ј and 5Ј-ATGGAGTTAGTTTGGGCAGCA-3Ј; ␥2a PS: 5Ј-GACCTCTCCGAA ACCAGGC-3Ј and 5Ј-GGGCCAGTGGATAGACCGA-3Ј; ␥3 PS: 5Ј-TCTGGACCTCTCCGAAACCA-3Ј and 5Ј-CCAGGGACCAAGGG ATAGACA-3Ј.
Analysis of S-S␥3 switch recombination junctions
Four hundred nanograms of genomic DNA isolated from B cells stimulated with LPS for 4 days (see above) was subjected to PCR amplification using Expand Hi-Fidelity Taq polymerase (Roche) and primers 3-H3 mod TG GCTTAACCGAGATGAGCC (modified from Ref. 26 ) and g3-2 TAC CCTGACCCAGGAGCTGCATAAC (26) . Six cycles of 94°C (1 min), 65-55°C (30 s; touch-down annealing), and extension at 72°C (2 min) were followed by 29 cycles of 94°C (30 s), 55°C (30 s), and 72°C (2 min). PCR products of three parallel reactions per sample were pooled, cleaned up with the QIAquick PCR purification kit (Qiagen), and cloned into pCR2.1 using the TOPO TA cloning kit (Invitrogen). Plasmids from individual bacterial colonies were sequenced in the Biopolymers Facility at Harvard Medical School by high-throughput colony sequencing. Switch junctions were identified using BLAST (MegaBLAST). Only S junctions longer than 100 bp were examined, and clonally related sequences were excluded from the analysis. Invariably, the sequences producing the most significant alignments were the genomic contigs NT_114985.2 (strain 129/SvJ) or NT_166318.1 (strain C57BL/6J), reflecting the mixed background of our mice (129ϫB6). Alignment of all sequences obtained in the entire analysis using Lasergene software (DNASTAR) did not reveal evidence of further polymorphisms in the S or S␥3 GL segments of our mice.
Statistical analysis
To determine p values, the 2-sample Student's t test (unpaired, 2-tailed, assuming unequal variances) was employed (as calculated by Microsoft Excel software) unless otherwise noted. All other statistical and non-linear regression analyses were done with Prism 4 (GraphPad Software). The error bars in Fig. 4B accommodate the SDs of the respective subset cellularities from mutant and control mouse cohorts, and were derived as follows: means (x ) of mutant (⌬) cell populations are expressed as fractions of control means (C). Therefore, the SDs of the quotients are calculated as CV ϭ ͌ CV ⌬ 2 ϩ CV C 2 where the coefficient of variation is defined as CV ϭ SD/x ; thus SD ϭ ͱͩ high B1 cells were sorted by cytometry and subjected to genomic PCR (pools of two mice per genotype). A 1:1 mixture of genomic DNA from cell lines harboring either only the floxed or the null Blm allele served as a reference (28) . A repetition of the experiment yielded similar results.
Results
B lineage-specific ablation of Blm results in impaired B cell development and maintenance
To delete Blm in B lineage cells, we bred mice harboring the constitutive null (⌬) (27) and floxed (f) Blm alleles (29) to mice expressing Cre recombinase under the mb1 regulatory elements (31) . Deletion analysis of selected lymphocyte populations in bone marrow, spleen, and peritoneal cavity from Blm f/⌬ mb1-Cre mice by semiquantitative PCR revealed an almost complete loss of the floxed allele in all B cell populations analyzed ( Fig. 1 ), as expected (31) . In contrast, T lymphocytes found in the peritoneal cavity were virtually devoid of deleted cells (Fig. 1) .
We analyzed selected cell populations of bone marrow, spleen, and peritoneal lavage for phenotypic abnormalities by flow cytometry. Strikingly, B220
ϩ B-lineage cells were dramatically underrepresented in the bone marrow of Blm f/⌬ Cre mice compared with Fig. 2A) . Absolute numbers of B220 ϩ bone marrow cells accounted for only about a third of those seen in controls ( Fig. 2A) . Accordingly, B cell development was severely compromised. While Fr. A-CЈ cells were relatively enriched, all later stages (i.e., Fr. D-F) were less frequent in mutant mice. Cellularities were significantly diminished in all subsets: Fr. A-CЈ were reduced by a fifth, and Fr. D, E, and F by three-fourths each ( ; B1a, p ϭ 0.001; B1b, p ϭ 0.009; n ϭ 6 for Blm f/⌬ Cre mice and n ϭ 12 for controls).
Likewise, the sizes of peripheral B cell populations were dramatically reduced in Blm-deficient mice. Consistently smaller spleens (data not shown) corresponded to cellularities of total CD19 ϩ and FO B cells of less than a fourth compared with littermate controls. Immature transitional B cells were reduced to a third and MZ B cells to 40% of control numbers (Fig. 2B) . Strikingly and very consistently, the CD5 ϩ B1a cell subset in the peritoneal cavities of mutant mice exhibited a severe atrophy. Peritoneal B1a cells accounted for only ϳ20% in frequency and 7% in absolute numbers compared with controls, whereas CD5 Ϫ B1b were somewhat more numerous (27% of controls; Fig. 2C ).
Taken together, the sizes of all major peripheral B cell subsets were drastically reduced in 
Compromised Ab responses in Blm-deficient mice
Even in naive mice, Abs of most Ig isotypes are detectable in considerable concentrations. Measuring steady-state Ab titers in nonimmunized animals, we found serum levels of all Ig isotypes drastically diminished in naive 7-to 10-wk-old mutant mice (Fig.  3A) . While IgA was least affected (43% of controls), IgG1, IgM, IgG2a, and IgG2b concentrations were at 26, 25, 20, and 16% of normal levels, respectively. Strikingly, IgG3 was consistently most dramatically reduced, present at only 4% of control titers (Fig. 3A) .
We then asked whether induced Ab responses would be similarly affected. Cohorts of Blm f/⌬ Cre and littermate control mice were immunized with the TI-II immunogen NP-Ficoll, and NPspecific IgM and IgG3 responses were measured in weekly intervals by ELISA. Conditional knockout mice produced only 12-15% specific IgM compared with controls after 1, 2, and 3 wk after immunization (Fig. 3B, upper panel) . Even more drastically, NPspecific IgG3 was detectable only in a few Blm f/⌬ Cre mice at all, and those showed titers hardly above the detection limit of the assay. The averages consequently amounted to Ͻ1% of control levels (Fig. 3B, lower panel) . After rechallenge, the differences became even more dramatic. NP-specific IgM concentrations dropped to Յ5% of the controls, whereas specific IgG3 was undetectable ( Fig. 3B and data not shown). Since challenge with TI-II Ags is not expected to produce large numbers of long-lived AFCs (33) , these data suggest that an already small pool of specific B cell precursors present in naive Blm f/⌬ Cre mice is further reduced in size by an inadequate and possibly abortive primary Ab response. Note that by using an i.p. immunization protocol, our experiments chiefly tested MZ B cell responses (33) . 41 -Ficoll in PBS on weeks 0 and 17, and NP-specific serum IgM and IgG3 levels were determined after 0 (preimmune), 1, 2, 3, 18, 19, and 20 wk by ELISA. Average concentrations (ϮSD) for each group are expressed relative to a pool of reference sera that were immunized using the same protocol (n ϭ 7-10 for sera collected after 0 -3 wk and n ϭ 4 for sera obtained after 18 -20 wk). Broken lines represent the detection limit of the ELISA ‫,ء(‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.005; ‫,ءءء‬ p Ͻ 0.0005 by Mann-Whitney U test). C, TD immune responses after primary and secondary immunizations. Cohorts of 11-to 19-wk-old Blm f/⌬ Cre and control mice immunized i.p. with 10 g NP 25 -CGG in alum on weeks 0 and 10 were bled on weeks 0, 1, 2, 3, 11, 12, and 13. NP-specific serum IgM, IgG1, and IgG2a titers were determined by ELISA and analyzed as in B. For each group, seven and five mice were analyzed on weeks 0 -3 and 11-13, respectively. D, Frequencies (ϮSD) of NP-specific IgM-, IgG1-, and IgG2a-secreting AFCs in the bone marrow of four Blm f/⌬ Cre and five control mice 12-13 wk after secondary immunization with NP 25 -CGG as determined by ELISPOT. The mice were part of the cohort shown in C. Statistical analysis was performed as in B.
TD B cell immunity was probed by immunization with NP-CGG followed by assessment of specific IgM-, IgG1-, and IgG2a Ab titers 1, 2, and 3 wk after a primary and a secondary immunization. In mutant mice, NP-specific IgM was reduced by 50 -60% throughout the experiment (Fig. 3C, upper panel) . Concentrations of specific IgG1 and IgG2a, however, were as low as 5% after primary challenge and dropped to Յ1% upon recall immunization (Fig. 3C, middle and lower panels) . To test whether the vestigial memory response in Blm f/⌬ Cre mice was reflected by lower frequencies of long-lived plasma cells, we enumerated AFCs in the bone marrow (where they preferentially reside (34)) by ELISPOT. Numbers of NP-specific IgM-producing AFCs were diminished by ϳ75% and IgG1-and IgG2a-secreting plasma cells by Ն90% (Fig.  3D) . The generation of long-lived AFCs and TD B cell memory is largely dependent on the GC reaction (35) . To test whether the GC reaction requires Blm, we monitored the formation and maintenance of GCs over time. Groups of Blm f/⌬ Cre and Blm f/ϩ Cre control mice were sacrificed 8, 12, and 18 days after immunization with SRBCs, and GC numbers and areas were determined in spleen sections by immunohistochemistry. As shown in Table I , we observed a tendency toward lower GC frequencies in conditional mutants (although this was not statistically significant). GC areas, however, were lower in Blm f/⌬ Cre mice throughout the analysis, exemplified by reduced frequencies of large GCs. The differences between mutants and controls increased with time, and by day 18 after immunization, the average frequency of large GCs in Blm f/⌬ Cre mice was only one eighth compared with control animals (Table I) . We conclude that GC formation can occur robustly in the absence of Blm (acknowledging the lower numbers of splenic B cells) but that GC maintenance is impaired and the reaction dies off more rapidly, providing a rationale for defective B cell memory and the low frequencies of long-lived AFCs in the bone marrow.
Taken together, the highly compromised short-term as well as long-term Ab responses mounted by mutant mice suggest as underlying cause a defective expansion and survival of Ag-specific B cells drawn from an already diminished pool of precursors. The observation that non-IgM (i.e., switched) isotypes were generally more severely affected raised the possibility of a dedicated role for Blm in CSR (see below).
Partial rescue of B cell subsets by p53 deficiency
To test whether p53-induced cell cycle arrest or apoptosis (36) is responsible for the small B cell compartments in Blm-deficient animals, we introduced a mutated Trp53 gene. p53 deficiency is known to substantially suppress the normally high apoptosis rates in Fr. A-C cells during B cell development in normal mice (37), and we had reported earlier a 55% rescue of thymocyte numbers in T cell-specific Blm knockout mice (28) . Indeed, we observed a ϩ/Ϫ and Trp53 Ϫ/Ϫ control littermates (controls set to 100%, n ϭ 5 or 6). Bone marrow populations were defined as in Fig. 2A modest, but consistent proportional increase of B lymphoid cells in bone marrow and spleen in Blm f/⌬ Cre mice upon p53 ablation (Fig. 4A, upper and middle panels) . The size of the B1a subset in the peritoneal cavity benefited from p53 deficiency in particular (Fig. 4A, lower panels) . As depicted in Fig. 4B , the absolute numbers of most B cell populations increased significantly as well; most notable were 2.8-, 2.1-, and 2.5-fold increases in bone marrow Fr. D, splenic FO, and splenic B1 cells, respectively. Serum Ig concentrations in naive mice, however, remained unchanged (data not shown).
Impact of Blm on CSR
Given the selectively low IgG3 serum levels and the particularly dwarfed IgG Ab responses and AFC numbers upon Ag challenge in mutant animals, we investigated a potential involvement of Blm in the mechanism of CSR. To this end, CD43
Ϫ splenocytes were labeled with CFSE to follow cell division and stimulated in vitro with the polyclonal mitogen LPS, either alone or in combination with IFN-␥. FACS analysis at day 4 revealed a prominent proliferative defect and excess cell death in mutant B cell cultures (Fig.  5A and data not shown). As proliferation is a mandatory prerequisite for CSR (19) and hence for meaningful data interpretation, we used p53-deficient B cells instead. Indeed, similar to the beneficial effects of p53 deficiency on B cell cellularities in vivo, significantly higher absolute numbers of live cells were recovered after identical in vitro culture using cells from (Fig. 5B) . Interestingly, p53 deficiency rescued cell survival to control levels, but the proportions of cycling cells recovered at day 4 remained unchanged ( Fig. 5B) . This indicates that the absence of p53 suppresses apoptosis induction but not cell cycle arrest in our system.
When testing p53-deficient splenocytes (Fig. 5C ), we consistently recovered substantially reduced proportions of switched B cells in Blm conditional knockout mice after 4 days of in vitro culture, that is, IgG3 ϩ , IgG2a ϩ , or IgG1 ϩ cells upon stimulation with LPS alone, LPS and IFN-␥, or LPS and IL-4, respectively. Switching to IgG2a and IgG3 was generally more affected than to IgG1 (Fig. 5C ).
During CSR, transcription through the S regions of participating isotypes generates sterile GL transcripts consisting of the noncoding I exon spliced to the C H exons of the respective isotype. The transcriptional rates correlate with CSR potential (21) . To test if the induction phase of CSR is compromised as a consequence of Blm deficiency, we assessed the relative levels of GL transcripts by quantitative real-time RT-PCR after 2 days of in vitro culture. As depicted in Fig. 5D , average GL I-C and target GL I␥3-C␥3, I␥2a-C␥2a, and I␥1-C␥1 transcripts were expressed at similar levels in appropriately stimulated Trp53 Ϫ/Ϫ Blm-deficient and Trp53 Ϫ/Ϫ Blm-competent cells. We conclude that the CSR induction phase remains uncompromised in Blm-deficient B cells. I promoter-driven transcription continues beyond the CSR event, generating PS transcripts with the I exon spliced to the CH exons of the switched isotype (38) . Compromised CSR is expected to yield lower than control levels of the respective PS transcripts. Indeed, we found the expression of I-C␥3, I-C␥2a, and I-C␥1 transcripts reduced to ϳ60 -70% of control levels averaging three independent experiments (Fig. 5D) .
However, since these effects were rather moderate and since Trp53 inactivation could not rescue the proliferation defect completely, we analyzed the switch efficiencies on a "per cell generation" basis; that is, we compared the percentages of switched cells that had undergone a specific number of cell divisions. Consistently poorer switch efficiencies across all generations would be indicative of a prominent Blm-dependent CSR defect. However, by averaging the same three experiments shown in Fig. 5D , we did not find such indication in either experimental setup (Fig. 5E) . Thus, these data argue against an essential role for Blm in the mechanism of CSR.
To determine whether the CSR junctions are normal, we cloned and sequenced S regions of p53-proficient B cells that had switched to IgG3 (i.e., S-S␥3 junctions) after LPS stimulation for 4 days. We found similar mutation frequencies in the vicinity (i.e., within a 300-bp window) of the junctions in B cells from Blmdeficient and control mice (1.28 ϫ 10 Ϫ2 (S; n ϭ 49) and 1.5 ϫ 10 Ϫ3 (S␥3; n ϭ 45) for mutants and 1.33 ϫ 10 Ϫ2 (S; n ϭ 37) and 2.0 ϫ 10 Ϫ3 (S␥3; n ϭ 47) for controls; differences not significant). To see whether the absence of Blm influences the repair phase of CSR, we determined the extent of S donor/S␥3 acceptor homology at the junctions. The length of microhomology was shown to increase upon inactivation of certain DNA repair factors, such as Mlh1 or Pms2 (26, 39) and thus deviate from the situation in wildtype mice whose S-S junctions display only little microhomology (40) . In Blm f/⌬ Cre B cells, a smaller number of S-S␥3 junctions showed no microhomology or small insertions, whereas junctions with 4 -11 bp of perfect donor/acceptor homology were slightly overrepresented (see insert in Fig. 5F ). Accordingly, the average length of overlap was greater in Blm-deficient B cells (2.1 Ϯ 0.3 bp SEM vs 1.3 Ϯ 0.3 bp in controls, n ϭ 70 for each genotype; insertions counted as "no microhomolgy"; p ϭ 0.03 by MannWhitney U test). Taken together, although Blm appears to be dispensable for the CSR mechanism, these data suggest that DNA ends are processed somewhat differently during CSR in the absence of Blm.
Reduced proliferative capacity due to impaired genomic stability entails altered turnover rates of several B-lineage subsets
We sought to specify the underlying causes for the in vivo defects in Blm f/⌬ Cre mice, especially for the remarkably contracted peritoneal B1a cell subset. To this end, we performed cell cycle analyses and examined metaphase spreads for the occurrence of chromosomal damage in class switch cultures. Upon stimulation of splenic B lymphocytes with anti-CD40 Ab and IL-4 for 3 days, considerably fewer B cells were in the S or G 2 /M phases of the cell cycle in Blm f/⌬ Cre vs control cultures, whereas the sub-G 1 fraction (i.e., apoptotic cells and cell debris) was approximately twice as large (Fig. 6A, upper panels) . Together with the data shown in Fig. 5, A and B, these data identify slowed (or suspended) cell cycle progression and increased apoptosis as the basis for the impaired in vitro and in vivo responses exhibited by mutant B cells. As depicted in Fig. 6A (lower panels) , cell cycle analyses of exclusively IgG1 ϩ events revealed similar differences between mutant and control B cells when compared with the unfractionated populations. This suggests that switched cells did not display grossly more accentuated cell cycle defects than did cells that had not or not yet undergone CSR, arguing against CSR-induced DSBs as a major cause.
When we analyzed metaphase spreads prepared from those cultures we encountered drastically elevated numbers of Blm-deficient cells that exhibited various manifestations of genomic instability (Table II) . Not only were the frequencies of aneuploid cells increased 1.8 -2.7-fold, but there was also ample evidence for aberrant replication among mutant B cell blasts. In three independent experiments, Blm f/⌬ Cre cells displayed 41-, 6.6-, and 3.4-fold as many abnormal DNA structures per chromosome than did control cells (Table II) . Thus, an inability to faithfully replicate genomic material upon rapid cell division provides the likely basis for the Blm-dependent compromised proliferative capacity.
In naive mice, we found Blm deficiency to affect different B cell subsets and Ig isotype levels to various extents (Figs. 2 and  3) , findings that represent a mere snapshot of a steady-state maintained by the interplay of multiple parameters in vivo. To establish how Blm-dependent genomic instability has shaped the phenotype observed in adult mice, we measured the turnover rates of selected lymphocyte subsets from bone marrow, spleen, and peritoneal cavity. Cohorts of Blm f/⌬ Cre and Blm
Cre control mice were fed BrdU-containing drinking water for 2 wk, and groups of four mice per genotype were sacrificed after particular time intervals during a chase period of several weeks. We detected no differences in the long-lived and rather nonproliferative (41) subsets of bone marrow Fr. F, splenic FO, splenic MZ, and peritoneal B2 cells (Fig. 6B) . The same was true for peritoneal T cells, which served as a Blm-proficient control population with no differential outcome expected (Fig.  6B) . In contrast, short-lived early B lymphoid fractions in the bone marrow (41) up to the Fr. E stage showed significantly slower turnover rates in Blm-deficient animals. Whereas Fr.
A-E cells from both groups incorporated BrdU to a similarly high degree (Ն80%) during the 2-wk pulse period, Blm f/⌬ Cre cells lost the label at a much slower rate (Fr. A-D: t 1/2 ϭ 4.5 and 2.8 days, and Fr. E: t 1/2 ϭ 3.9 and 2.4 days for mutant and control mice, respectively). A different situation emerged in the subset of slowly dividing peritoneal B1a cells. Mutants entered the chase period with a higher fraction of BrdU ϩ B1a cells (43.8 Ϯ 5.3% vs 28.8 Ϯ 5.5% SEM) whose numbers, however, declined more rapidly than in controls, translating into calculated t 1/2 of 26 days in Blm f/⌬ Cre and 121 days in Blm f/ϩ Cre mice (Fig. 6B) .
These data indicate that in situations where cells undergo multiple cell divisions in rapid succession (Fr. CЈ and early Fr. D), Blm-dependent decelerated cell cycle progression delays the passage of B lymphoid cells through the early developmental stages. In turn, since Fr. A-D cells feed the subsequent stage of immature Fr. E cells (characterized by little proliferation and massive cell death in normal mice (16) ), this subset, too, loses BrdU ϩ cells at a slow kinetics in Blm f/⌬ Cre mice. In contrast, the faster turnover rates of mutant peritoneal B1a cells appear symptomatic in that an atrophic population of naturally self-renewing cells (18) undergoes slow but continuing homeostatic proliferation, but it fails to fill up the compartment to wild-type levels, likely due to excess apoptosis. a Chromosome breaks, translocations, small marker chromosomes, double minutes, and prematurely condensed chromosomes were scored on Giemsa-stained metaphase spreads prepared from CD43 Ϫ B cells that had been stimulated with anti-CD40 and IL-4 for 3 days. Cells from one mouse per genotype were used for each experiment.
Development of B cell lymphomas in p53-deficient Blm f/⌬ Cre mice
We monitored several cohorts of mice during a 14-mo period for the occurrence of B cell lymphomas. Since it is now well established that Blm deficiency entails only a mild predilection for tumor development in the mouse (28 -30) , we sought to facilitate tumor induction by analyzing cohorts of Blm-deficient and Blmproficient mice on either Trp53-null or Trp53-heterozygous backgrounds. Furthermore, to stimulate GC formation and thereby induce CSR-dependent DNA strand breaks, we immunized the mice twice with SRBCs. As evident from Fig. 7A , the survival curves of Blm f/⌬ Cre and Cre Ϫ control mice did not differ significantly, irrespective of p53 proficiency.
We nevertheless determined the tumor spectra in the carcasses. Necropsy revealed that thymic T cell lymphoma caused terminal disease in 6 of 13 Trp53 Ϫ/Ϫ control mice (47%), whereas none of them had developed a B cell malignancy (Fig. 7B and Table III) . In contrast and unexpectedly, thymic lymphoma was found only in 1 of 10 Blm f/⌬ Cre Trp53 Ϫ/Ϫ animals, while a B220 ϩ B cell lymphoma was prevalent in 6, as revealed by immunohistochemistry (Fig. 7C and Table III ). The Blm mutants developed B cell malignancies slightly earlier (113 Ϯ 32 days) than did the controls in succumbing to thymic lymphoma (135 Ϯ 39 days), but the difference was not significant. Of the five moribund Trp53 ϩ/Ϫ control mice encountered during the course of the experiment, none had developed either thymic or B cell lymphoma. However, of six terminally sick Blm f/⌬ Cre Trp53 ϩ/Ϫ animals, one and three came down with thymic and B cell lymphoma, respectively (Table III) (Table III and Fig. 7C ). We conclude that B lineage-specific ablation of Blm promotes B cell lymphoma development. This effect, however, only becomes significant upon concomitant inactivation of the tumor suppressor p53.
Discussion
We report a vital role for the BS helicase in all major aspects of the B cell life cycle, manifest in disturbed B cell immunity and tumor development in its absence. Since pleiotropic inactivation of the murine Blm gene confers embryonic lethality (27) , we generated tissue-specific Blm knockout mice using the mb1-Cre strain that was shown to yield early and specific deletion of floxed target genes in the B cell lineage (31), a result we could confirm using our Blm f allele (Fig. 1) . We thus conclude that the findings reported herein are B cell autonomous in nature.
In the bone marrow of Blm mutants, B220 ϩ B lineage cells were dramatically underrepresented, indicating impaired B cell development. This effect was primarily attributable to a severe attrition of Fr. D-F cells. Since rearrangement of the Ig H chain genes occurs during the Fr. A-C developmental stages (14) , these findings could be explained by an impaired formation of functional V H D H J H joints and a subsequent failure of developing B cells to pass the pre-BCR checkpoint. However, a major role for Blm in the mechanism of VDJ recombination has been ruled out before (28, 42, 43) . Specifically, we previously reported normal VDJ recombination efficiencies of Tcrb genes in Blm-deficient thymocytes and the inability of a rearranged TCR transgene to rescue atrophic thymi in T cell-specific Blm knockout mice (28) . We therefore favor an alternative explanation. The proliferative burst triggered by pre-BCR expression is considered substantial (Յ6 cycles) (44, 45) and divisions occur in rapid succession (Ն6.5 h/cycle) (44) , imposing intense replicative stress on developing B cells. BS cells are well known for their inability to cope with such stress, as they exhibit delayed Okazaki fragment growth, accumulate abnormal replication intermediates, and are unable to efficiently restart replication following replication fork demise (46 -48) . Collapsing replication forks are thought to occur in every replicative cell cycle, imposing a potentially serious problem for rapidly dividing cells (49) . Blm is recruited to sites of damaged replication forks (50) where it can aid fork reinitiation through potentially several means, including the promotion of fork regression to allow lesion bypass of the leading strand (51) (for detailed discussion, see Refs. 5, 49). The helicase's proposed function as a remover of bulky DNA secondary structures to avoid stalling and breakdown of replication forks in the first place (23, 24) was already mentioned. Thus, an inability of Blm-deficient developing B cells to suppress replication errors will manifest in delayed cell cycle progression (see the slow turnover rates of Blm f/⌬ Cre Fr. A-E cells in Fig. 6B ), likely accompanied by increased apoptosis rates (52) as observed in mature B cells (see below).
In the spleens of Blm f/⌬ Cre mice, we observed greater attrition of the B2 than the MZ cell compartment (Figs. 2B and 4B) . Most affected by the absence of Blm, however, were B1 cells. We encountered an at best rudimentary B1a cell compartment, amounting to Ͻ10% and Ͻ20% of control numbers in peritoneal cavity and spleen, respectively (Figs. 2C and 4B ). The proliferative capacity of mutant B cells was remarkably impaired upon in vitro culture with several stimuli such as LPS or CD40 ligation. Increased global genomic instability was determined to be the underlying reason, manifesting in elevated levels of chromosomal structural abnormalities and chromosome loss during replication (Table II) . This, in turn, led to elevated apoptosis rates (Figs. 5B and 6A) and a combination of cell cycle arrest and decelerated cell cycle progression (Figs. 5, A and B, and 6 ).
These findings are in line with earlier studies in humans (47, 48) and mice (28 -30) , and they represent classical features of BLMdeficient cells (5, 7) . B1a, B1b, FO, and MZ B lymphocytes might exhibit differential sensitivity to or suffer from variable degrees of replication stress during their respective life cycles, possibilities that cannot be excluded, but are hard to test for in our model. In the light of our findings, however, we consider the following scenario most pertinent. The MZ and B2 cell pools are constantly being replenished through bone marrow-derived precursors that are backed up by Blm-proficient HSCs. B1a cells, on the other hand, originate from fetal and postnatal precursors, and yet they are otherwise dependent on self-propagation throughout adulthood (16, 18) . Ongoing self-replenishment is expected to be strongly handicapped as we detected near complete Blm deletion in peritoneal B1a cells (Fig. 1) . Concordantly, while no differences in the turnover rates of mature B2 and MZ cell subsets were seen in Blm f/⌬ Cre vs control mice, we found shorter half-lives of Blm-deficient B1a cells in the peritoneum (Fig. 6B) , reflecting the strong but futile drive to replenish the main producers of "natural Abs" (15) .
BLM and p53 physically and functionally interact in vivo (50, 53) . Although p53-dependent apoptosis was found deregulated in cell lines from BS patients (53, 54) , BS cells were shown to undergo p53-dependent apoptosis at stalled replication forks, and p53 deficiency prevents death of damaged BS cells (52) . Also, Lu and Osmond reported a marked suppression of normally high apoptosis rates in early B cell development upon Trp53 inactivation (37 (Fig. 4B) . However, in a T cellspecific Blm knockout model, p53 inactivation had a stronger effect than seen here, as severely reduced thymic cellularities were rescued almost 3-fold (28) . Furthermore, in Trp53 Ϫ/Ϫ scid mice, T cell development was promoted while B cell hematopoiesis remained essentially unaffected (55) . In this respect, the findings reported herein are in line with the notion that p53-dependent cell survival plays a more significant role in the T cell vs the B cell lineage (55, 56) .
We found low levels of IgM, IgG1, IgG2b, IgG2a, and IgA, but extraordinarily reduced IgG3 concentrations in the sera of naive mutant animals (Fig. 3A) . Similar to our findings, certain gene mutations in mice were reported to produce a substantial depletion of the B1a cell compartment while affecting less the conventional B2 or MZ cells. As expected, these strains exhibited marked IgM hypoglobulinemia, along with comparably low concentrations of several (57) or all other isotypes (58). Our distinct Ig isotype pattern prompted us therefore to test whether Blm might be involved in CSR.
Because of the detrimental effect of Blm ablation on proliferation and survival (Fig. 5A) , we tested B cells doubly deficient for Blm and p53, whose proliferative capacity indeed proved to be more similar albeit not identical to control levels (Fig. 5B) . We detected substantially reduced class switching to IgG1, IgG2a, and IgG3 in double-mutant splenic B cells, and the abundance of sterile PS I-C␥1, I-C␥2a, and I-C␥3 transcripts was reduced as well (Fig. 5, C and D) . However, PS transcripts were still at Ͼ50% of control levels, contrasting with other reports that showed obligatory roles for ATM and 53BP1 in CSR. Here, quantities of productive transcripts in stimulated mutant B cells were insignificant (59, 60) . Most importantly, the frequencies of switched cells per a Mice were immunized twice with SRBCs, monitored for 350 days, sacrificed when in moribund condition (see Fig. 7A ), and subjected to necropsy; spleens and macroscopically cancerous organs were examined histopathologically on H&E-stained tissue sections; cases with diagnosed lymphoma were subsequently classified by immunohistochemistry.
b Two mice with B cell lymphoma and hemangiosarcoma, one mouse with rhabdomyosarcoma and hemangiosarcoma. generation were not significantly different between Blm/p53 double-deficient and control B cells across all generations and culture conditions. We thus ascribe the reduced switch efficiencies to the impaired proliferative capacity resulting from an inability of Blmdeficient B cells to cope with replicative stress. We did not find evidence for the possibility that the observed cell death was a consequence of the CSR process itself, that is, that an excess number of induced DSBs remained unrepaired in switching Blm-deficient B cells. In fact, the impairment in CSR was consistently mildest in mutant B cells stimulated with LPS and IL-4, while those cultures uniformly produced the highest yields of switched (i.e., IgG1 ϩ ) cells compared with the other culture conditions. We add that a possible minor function of Blm in the early phase of CSR is probably undetectable using our system due to the obligatory role of proliferation in the CSR process. However, we observed a shift toward microhomology-mediated end joining in S-S␥3 junction sequences amplified from activated Blm-deficient B cells (Fig. 5F ). This effect, although moderate, is generally compatible with a role for Blm in the resolution phase of CSR, that is, in the synapsis and/or joining of the participating S regions. The relevance of this finding remains unclear at this point and its elucidation will be an interesting subject for future experiments. A possible direct role for Blm could include the disruption of DNA structures bearing only short stretches of homology, thereby disfavoring the generation of CSR joints that rely on microhomologies for their resolution. This would be reminiscent of the presumed role of RecQ helicases as fidelity regulators during homologous recombination (suppressing illegitimate recombination events (5)). Indirectly, a lack of Blm could interfere with the proper function of certain interaction partners, such as ATM (61) or the mismatch repair factor Mlh1 (25) that are known to be involved in CSR (26, 59, 62) . For example, longer stretches of microhomology were also found in switched B cells deficient for Mlh1, albeit the effect was stronger (26) .
BS patients develop tumors of various types at a high incidence, prominently including B cell neoplasias (7, 8) , yet most mouse models for BS exhibit only a mild propensity for cancerogenesis (28 -30) . The reason for this discrepancy is unclear, but a certain functional redundancy among the five mammalian RecQ family members (RECQ1, BLM, WRN, RECQ4, and RECQ5 in man), differentially accentuated in rodents and primates, is a possibility (63) . Also, a role for Blm in telomere maintenance is emerging (64) , an effect hard to model in mice due to the inherently longer telomeres of murine chromosomes. Indeed, in an attempt to faithfully model Werner syndrome, a premature aging disease caused by WRN mutation, the full spectrum of the human disease (including an increased cancer incidence) was only unveiled after induced exhaustion of telomere reserves in engineered mice that lacked both the Wrn gene and the telomerase RNA template Terc (65) . In the Wrn Ϫ/Ϫ Terc Ϫ/Ϫ Blm tm3BrdϪ/Ϫ model described by Du et al. (64) , cancer development was not investigated. But since this model used a hypomorphic Blm allele (30, 66) , it is tempting to speculate that Terc deficiency in Blm f/⌬ mb1-Cre mice could well accelerate the development of B cell lymphomas.
We used inactivation of the gatekeeper tumor suppressor p53 to facilitate lymphoma development in a small cohort of mice. p53-deficient mice are known to frequently develop lymphomas, although predominantly of thymic origin (32, 67) . If ablation of Blm in the B cell lineage actually facilitated the development of B cell malignancies, we would expect a shift in the tumor spectrum favoring B cell-over T cell-derived lymphomas. This is what we observed here. Although the lifespans of Blm f/⌬ Cre Trp53 Ϫ/Ϫ and control Trp53 Ϫ/Ϫ mice were similar (Fig. 7A) , more than half of the double mutants exhibited B cell neoplasias at the time of death (Table III) . We conclude that Blm deficiency in B lymphocytes exerts a mild tumor-promoting effect in mice. This is in line with Luo et al., who reported late cancer development in 29% of mice homozygous for the hypomorphic Blm tm3Brd allele by the age of 20 mo, including lymphomas (66) . Interestingly, judging from their immunohistochemical phenotype, the six B cell lymphomas found in Blm f/⌬ Cre Trp53 Ϫ/Ϫ animals appear to have developed from GC or post-GC B cells. This finding is reminiscent of the situation in BS patients where non-Hodgkin's lymphomas dominate the spectrum of hematogenous malignancies (Ref.
8, yet with unknown p53 status). Most non-Hodgkin's lymphomas are known to originate from GC or post-GC B cell precursors (68) .
With the methodology employed, we cannot gauge to which extent unfaithfully repaired AID-dependent DNA strand breaks generated during CSR or somatic hypermutation contribute to lymphoma development in immunized Blm f/⌬ Cre Trp53 Ϫ/Ϫ mice. Franco et al. (69) found dramatic levels of chromosomal instability in switching B cells deficient for histone H2AX in vitro, and those high levels were independent of p53 proficiency. In contrast to H2AX Ϫ/Ϫ mice, however, H2AX Ϫ/Ϫ Trp53 Ϫ/Ϫ mice are dramatically cancer prone (70, 71) , arguing that the generation of potentially oncogenic translocations can occur in the presence of p53 (similar to our findings, e.g., Table II ). Defective p53-dependent checkpoints may, however, allow the propagation and outgrowth of post-GC B cells bearing them (69) . It will be interesting to delineate to which extent the BCR loci are involved in oncogenic translocation events in lymphomas from Blm f/⌬ Cre Trp53 Ϫ/Ϫ animals. In addition to its functions as roadblock remover during replication, facilitator of replication fork restarts, and antirecombinase (as discussed above), the tumor suppressor functions exercised by Blm are thought to depend on its role as a suppressor of crossover formation (e.g., through double Holiday junction dissolution (6)). These functions in turn counteract the occurrence of loss of heterozygosity (66) and global genomic instability (29) , crucial processes underlying tumor formation.
In conclusion, we generated a mouse model for the immunodeficiency in BS highlighting disturbances in key aspects of B cell biology. We propose that, together with a Blm-dependent T cell defect we described earlier (28) , an impairment in both arms of the adaptive immune system accounts for the compromised immunity seen in affected individuals (72) . However, besides the issues concerning embryonic lethality and tumor incidence mentioned above, we see further evidence for an accentuation of Blm function in mice vs man. Although low Ig levels of one or several isotypes are typically found in most BS patients, B cell numbers are largely normal, although at the lower end of the spectrum (9, 11). Unfortunately, specific information on the distribution of different B cell subsets in affected individuals (e.g., size of the B1 cell compartment) is not available to extend the comparison. Nevertheless, it will be interesting to explore the impact of postulated backup mechanisms in mice that could fill in upon Blm ablation, for example, by a double-knockout strategy. RECQ5, for instance, exhibits similar biochemical and functional properties (63) , and a pan-Recql5-deficient mouse, although developmentally normal, revealed a prominent tumor suppressor function for this RecQ helicase as well (73) .
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